EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders

Hyeon Ji Jeon, Jin Seok Moon iD, Hye Min Jeong, Won Yeong Bang iD, Hayoung Kim, Donggyu Kim, Minhye Shin, Jungwoo Yang iD, Jongbeom Shin, Young Hoon Jung iD

Nutrients · 29.07.2026 · 18 (15) · 2466

DOI: 10.3390/nu18152466 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 29.07.2026. Verfasst von Hyeon Ji Jeon und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Metabolome, Probiotics, Colonic Diseases, Functional. Die Arbeit nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry, National Research Foundation of Korea, Ildong Bioscience, Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Functional bowel disorders (FBDs) are chronic gastrointestinal conditions that substantially impair quality of life. This randomized, double-blind, placebo-controlled trial investigated the effects of Heyndrickxia coagulans IDCC 1201 (COA 1201) in adults with FBD.

Methods

Participants received COA 1201 or a placebo for 8 weeks, with outcomes assessed using the irritable bowel syndrome (IBS) Symptom Severity Score (IBS-SSS), IBS Quality of Life (IBS-QOL), and bowel activity measures. And Fecal microbiome and metabolomics were measured by 16S rRNA gene sequencing gas chromatography-mass spectrometry, respectively.

Results

Both groups showed improvement from baseline, but COA 1201 produced greater symptom relief, particularly in abdominal bloating, post-defecation discomfort, and the body image domain of IBS-QOL. Fecal microbiome profiling revealed modest changes in global diversity, yet taxa linked to saccharolytic activity and short-chain fatty acid production—including Ruminococcus bromii, Agathobacter rectalis, and Bifidobacterium—were enriched in participants receiving COA 1201, whereas Clostridium leptum increased in those receiving a placebo. Untargeted metabolomics demonstrated distinct metabolic signatures between groups, confirmed by supervised partial least squares discriminant analysis. Exploratory metabolites were identified using variable importance in projection scores (>1.5), statistical significance (p < 0.05), and absolute log2 fold change (>1). Alanine and proline emerged as time-dependent metabolites, while tryptophan, lactic acid, and phytosphingosine were specifically associated with COA 1201 treatment.

Conclusions

Collectively, these findings suggest that COA 1201 alleviates FBD symptoms by modulating the gut microbiome and metabolome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeMetabolomeProbioticsColonic Diseases, FunctionalAdultFemaleHumansMaleMiddle AgedDouble-Blind MethodFecesIrritable Bowel SyndromeMetabolomicsQuality of LifeRNA, Ribosomal, 16STreatment Outcome

Stichwörter der Autor:innen

Heyndrickxia coagulansfecal metabolomicsfunctional bowel disordersgut microbiomeprobiotics

Substanzen

RNA, Ribosomal, 16S

Autor:innen und Institutionen

  • School of Food Science and Biotechnology, Kyungpook National University, Daegu 41566, Republic of Korea.
  • ILDONG Bioscience Co., Ltd., 17 Poseunggongdan-ro, Poseung-eup, Pyeongtaek-si 17957, Republic of Korea.
  • Department of Microbiology, College of Medicine, Inha University, Incheon 22212, Republic of Korea.
  • Department of Microbiology, College of Medicine, Dongguk University, 123 Dongdae-ro, Gyeongju 38066, Republic of Korea.
  • Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon 22212, Republic of Korea.

ORCID-Profile: Jin Seok Moon, Won Yeong Bang, Jungwoo Yang, Young Hoon Jung

Förderung

  • Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry
  • National Research Foundation of Korea
  • Ildong Bioscience, Co., Ltd.
  • Hanwoomul-Phagi Basic Research Program through the National Research Foundation of Korea (NRF) grant
  • Korean government

Zitieren

APA

Jeon, H. J., Moon, J. S., Jeong, H. M., Bang, W. Y., Kim, H., Kim, D., Shin, M., Yang, J., Shin, J., & Jung, Y. H. (2026). Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. Nutrients, 18(15), 2466. https://doi.org/10.3390/nu18152466

Vancouver

Jeon HJ, Moon JS, Jeong HM, Bang WY, Kim H, Kim D, et al. Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders. Nutrients. 2026;18(15):2466. doi:10.3390/nu18152466

BibTeX
@article{Jeon2026,
  author = {Jeon, Hyeon Ji and Moon, Jin Seok and Jeong, Hye Min and Bang, Won Yeong and Kim, Hayoung and Kim, Donggyu and Shin, Minhye and Yang, Jungwoo and Shin, Jongbeom and Jung, Young Hoon},
  title = {Heyndrickxia coagulans IDCC 1201 Alters Gut Microbiome and Metabolome in Patients with Functional Bowel Disorders},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {15},
  pages = {2466},
  doi = {10.3390/nu18152466}
}
Kostenlos starten →